Gossamer Bio Receives Nasdaq Delisting Notice for Failing $1.00 Minimum Bid Price Requirement
Gossamer Bio, Inc. (GOSS) announced on April 8, 2026, that it received a written notice from Nasdaq's Listing Qualifications Department regarding non-compliance with the minimum bid price requirement. The company's common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, specifically from February 24, 2026, through April 7, 2026. This notice does not result in immediate delisting, as Gossamer Bio has a 180-calendar-day period, until October 5, 2026, to regain compliance. Failure to meet this deadline could lead to a potential transfer to the Nasdaq Capital Market and necessitate actions such as a reverse stock split to cure the deficiency.
Key Highlights
- Gossamer Bio received a notice on April 8, 2026, from Nasdaq regarding non-compliance with Nasdaq Listing Rule 5450(a)(1).
- The company's common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, from February 24, 2026, through April 7, 2026.
- Gossamer Bio has 180 calendar days, until October 5, 2026, to regain compliance with the Minimum Bid Price Requirement.
- To regain compliance, the common stock must achieve a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
- If compliance is not regained by October 5, 2026, the company may be eligible for an additional 180-day period if it transfers to the Nasdaq Capital Market and meets other listing standards, potentially requiring a reverse stock split.
Price Impact
More from GOSS
More in Delisting/Transfer